Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma

European Journal of Surgical Oncology

Volumn 33, Issue 2, 2007, Pages 208-212

  Hsia, C Y ^a,b   Huo, T I ^a,b   Chiang, S Y ^c   Lu, M F ^c   Sun, C L ^c   Wu, J C ^a,b   Lee, P C ^b   Chi, C W ^a,b   Lui, W Y ^a,b   Lee, S D ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c Targetgen Inc   (Taiwan)

Author keywords

Hepatocellular carcinoma; Hepatocyte growth factor; Interleukin 10; Interleukin 6; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; SCATTER FACTOR; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER SIZE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; ANGIOGRAPHY; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 33847344307     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.10.036     Document Type: Article

References (39)

1. Kao J.H., and Chen D.S. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 25 (2005) 696-703
2. Hussain S.A., Ferry D.R., El-Gazzaz G., et al. Hepatocellular carcinoma. Ann Oncol 12 (2001) 161-172
3. Nomura F., Ishijima M., Kuwa K., Tanaka N., Nakai T., and Ohnishi K. Serum des-gamma carboxyprothrombin levels determined by a new generation of sensitive immunoassay in patients with smallsized hepatocellular carcinoma. Am J Gastroenterol 94 (1999) 650-654
4. Mita Y., Aoyagi Y., Yanagi M., Suda T., Suzuki Y., and Asakura H. The usefulness of determining des-gamma carboxyprothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 (1998) 1643-1648
5. Sugimoto H., Takeda S., Inoue S., Kaneko T., Watanabe K., and Nakao A. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int 23 (2003) 38-44
6. Marrero J.A., Su G.L., Wei W., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in American patients. Hepatology 37 (2003) 1114-1121
7. Yoshida S., Kurokohci K., Arima K., et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 20 (2002) 305-309
8. Wang S.S., Lu R.H., Lee F.Y., et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 25 (1996) 166-171
9. Song B.C., Suh D.J., Yang S.H., et al. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol 35 (2002) 398-402
10. Tsai J.F., Jeng J.E., Chuang L.Y., et al. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol 24 (2003) 291-298
11. Tsai J.F., Jeng J.E., Chuang L.Y., et al. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scand J Gastroenterol 40 (2005) 68-75
12. Sedlaczek N., Hasilik A., Neuhaus P., Schuppan D., and Herbst H. Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 88 (2003) 733-739
13. Marrero J.A., and Lok A.S. Newer markers for hepatocellular carcinoma. Gastroenterology 127 5 suppl 1 (2004) S113-S119
14. Fujiyama S., Tanaka M., Maeda S., Ashihara H., Hirata R., and Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62 suppl 1 (2002) 57-63
15. Chau G.Y., Wu C.W., Lui W.Y., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231 (2000) 552-558
16. Fortis C., Foppoli M., Gianotti L., et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 104 (1996) 1-5
17. Shin H.D., Park B.L., Kim L.H., et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 12 (2003) 901-906
18. Reichner J.S., Mulligan J.A., Spisni R., Sotomayor E.A., Albina J.E., and Bland K.I. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol 5 (1998) 279-286
19. Salgado R., Junius S., Benoy I., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103 (2003) 642-646
20. Chung Y.C., and Chang Y.F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83 (2003) 222-226
21. Wu C.W., Wang S.R., Chao M.F., et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91 (1996) 1417-1422
22. Daveau M., Scotte M., Francois A., et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36 (2003) 130-141
23. Vejchapipat P., Tangkijvanich P., Theamboonlers A., Chongsrisawat V., Chittmittrapap S., and Poovorawan Y. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 39 (2004) 1182-1188
24. Guirouilh J., Le Bail B., Boussarie L., et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 34 (2001) 78-83
25. Tanaka K., Miki C., Wakuda R., Kobayashi M., Tonouchi H., and Kusunoki M. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 39 (2004) 754-760
26. Yamagamim H., Moriyama M., Matsumura H., et al. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 95 (2002) 824-834
27. Parr C., Watkins G., Mansel R.E., and Jiang W.G. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10 (2004) 202-211
28. Bruix J., Sherman M., Llovet J.M., et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
29. Yeh C.N., Lee W.C., Jeng L.B., and Chen M.F. Hepatic resection for hepatocellular carcinoma in Taiwan. Eur J Surg Oncol 28 (2002) 652-656
30. Higashio K., Shima N., Goto M., et al. Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem Biophys Res Commun 170 (1990) 397-404
31. Gherardi E., and Stoker M. Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cells 3 (1991) 227-232
32. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3 (1991) 67-86
33. Efimova E.A., Glanemann M., Liu L., et al. Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res 36 (2004) 300-307
34. Sakon M., Kita Y., Takeda Y., et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 29 (1999) 110-113
35. Howard M., O'Garra A., Ishida H., de Waal Malefyt R., and de Vries J. Biological properties of interleukin 10. J Clin Immunol 12 (1992) 239-247
36. Hirano T., Akira S., Taga T., and Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 11 (1990) 443-449
37. Coskun U., Bukan N., Sancak B., et al. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51 (2004) 209-213
38. Lohe F., Angele M.K., Gerbes A.L., Lohrs U., Jauch K.W., and Schauer R.J. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 31 (2005) 994-999
39. Kawasaki S., Makuuchi M., Miyagawa S., et al. Results of hepatic resection for hepatocellular carcinoma. World J Surg 19 (1995) 31-34